Statins, skeletal muscle, and ryanodine receptor activation: resolving a 30-year mystery behind statin myotoxicity

Statins are foundational therapies in cardiometabolic disease prevention, yet their clinical utility is could be limited by muscle-related adverse effects whose molecular origins have remained incompletely understood. In a landmark structural study, atorvastatin is shown to bind directly to skeletal muscle RyR1 in a unique triplet configuration, sequentially destabilizing the closed channel and promoting pathological Ca²⁺ leak. This work provides the first atomic-level explanation for statin-induced myopathy and reveals why individuals with RyR1 gain-of-function variants—already known to be overrepresented among statin-intolerant patients—are particularly vulnerable to muscle toxicity. For endocrinology, these findings are especially significant: statins remain central interventions in dyslipidemia, diabetes, obesity, and metabolic syndrome, and intolerance disproportionately affects individuals with high cardiometabolic burden. By establishing a receptor-mediated mechanism of statin myotoxicity, this study opens the door to genotype-informed statin prescribing, rational engineering of “RyR1-silent” lipid-lowering agents, and improved long-term adherence in patients with endocrine and metabolic disorders. These findings represent a major advance at the interface of metabolism, muscle physiology, and precision pharmacology, with the potential to reshape clinical practice across the endocrine continuum.